• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSX:MSCL)

9.380 +0.260 (+2.85%)
Delayed Quote Updated: 11:48 AM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,008
Open 9.230
Bid (Size) 9.350 (1)
Ask (Size) 9.580 (2)
Prev. Close 9.120
Today's Range 9.050 - 9.380
52wk Range 0.6300 - 18.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 24, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
February 18, 2026
From Satellos Bioscience Inc.
Via Business Wire

Performance

52-Week Range 50.6% below 52-week high
9.380
0.6352W Low 18.9852W High
1 Week 6.2% below 1-week high
9.021W Low 10.001W High

(MSCL) traded between $0.63 and $18.98 over the past 52 weeks and last traded at $9.38, 50.6% below its 52-week high. Over the past week it ranged between $9.02 and $10.00.

Past 12 Months
+1.4%
-26.0%
-31.5%
-1.3%
+1240.0%
+1167.6%
1W +$0.13
1M -$3.30
3M -$4.31
6M -$0.12
YTD +$8.68
1Y +$8.64

MSCL was +1167.6% over the past year, -1.3% over six months, +1240.0% year to date, +1.4% in the last week.

12 Months vs Market
MSCL
+1167.6%
DIA
+12.3%
SPY
+14.2%
QQQ
+16.9%
IWM
+13.4%

Over the past 12 months MSCL returned +1167.6% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +16.9% and IWM (Russell 2000) +13.4%.

Volume & Liquidity 0.41× 3-mo avg
Today 5,008 3-mo avg 12.2K
1W
10.2K
1M
11.0K
3M
12.2K
6M
16.0K
YTD
83.7K
1Y
95.3K

MSCL most recently traded 5,008 shares against a 3-month average daily volume of 12.2K.

More News

Read More
News headline image
Satellos to Participate in Upcoming Investor Conferences
February 17, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 12, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 10, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
February 09, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
February 06, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
February 05, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
January 29, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
January 28, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
December 09, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in December Investor Conferences
November 25, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
November 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
November 14, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in November Investor Conferences
October 30, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
October 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
October 10, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
September 29, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
September 22, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
August 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
August 13, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 05, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
July 16, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire

Frequently Asked Questions

Is MSCL publicly traded?
Yes, MSCL is publicly traded.
What exchange does MSCL trade on?
MSCL trades on the Toronto Stock Exchange
What is the ticker symbol for MSCL?
The ticker symbol for MSCL is MSCL on the Toronto Stock Exchange
What is the current price of MSCL?
The current price of MSCL is 9.380
When was MSCL last traded?
The last trade of MSCL was at 10/23/26 11:48 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap